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Epithelioid hemangioendothelioma is a rare connective tissue tumor of vascular origin. It is most commonly found
in young to middle aged women, and its clinical behavior is remakably variable from an indolent metastatic tumor
to an aggressive rapidly growing neoplasm. Most tumors are diagnosed in an advanced unresectable phase and
when clinically aggressive, require systemic cytotoxic treatment of sarcoma. Then, the 5-year survival rate after
chemotherapy does not exceed 30%. Antiangiogenics are active in selected sarcoma subtypes: pazopanib, the
only anti angiogenic registered agent for sarcoma provides a median PFS of 4.5 months only in the pivotal
study. Their activity in EHE has been reported but long term outcome of these patients remain unreported.
We report a case of a female patient with HEH who was treated with pazopanib for almost 8 years. Pazopanib
therapy resulted in clinical improvement of symptoms and durable stabilization of liver tumors and lung lesions.
Conclusion: Pazopanib is a promising therapeutic option in patients with HEH.
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cular tumour first reported as intravascular bronchiolo-
alveolar tumor by Dail and Liebow (1975) in a patient
with a lung variant of the disease (LEH) [1]. EH has been
also named sclerosing interstitial vascular sarcoma and
sclerosing endothelial tumor, before the term EH was in-
troduced by Weiss and Enzinger [2] as a clinical state
between benign hemangioma and angiosarcoma. EHE
originate from endothelial cells and generally occurs in
the liver, lungs, and other soft tissues. Positivity of
endothelial differentiation markers, such as factor VIII-
dependent antigen, CD-34, and CD-31, as well as vascu-
lar invasion and an infiltrating growth pattern (except in
the portal region) are important in the diagnosis of epi-
thelioid hepatic hemangioendothelioma [3,4]. Specific
mutation involving the 1p36.3 chromosomal region been
demonstrate in subsets of these tumors [5]. Chronic liver
disease is not considered a significant cause of HEHE [6]
.In almost half of the cases, HEHE is diagnosed at meta-
static stage mostly with pulmonary and bone localization
[7]. EH is characterized by an often unpredictable* Correspondence: Olfa.derbel@lyon.unicancer.fr
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unless otherwise stated.clinical course. Whereas some patients present a rapidly
progressive disease, others may remain stable for several
years. However, overall, HEHE have a poor prognosis:
5-year overall survival of HEH patients after standard
primary radical treatment is 30% and therefore, it is
one of the liver malignancies associated with a better
prognosis [8]. There are few standard options and con-
sensus reports for the management of EHE. Surgery with
partial hepatectomy or liver transplantation is the first-
line treatment when HEH is confined to the liver. Che-
motherapeutic agents reported as treatment regimens are
Doxorubicin, Vincristine, Fluorouracil (5-FU), and Inter-
feron (IF)-alpha 2b [3]. Indolent EHE stable and non evo-
lutive without any treatment have also been reported.
Vascular endothelial growth factor (VEGF) and the VEGF
receptor are detectable on EHE tumor cells [9], suggest-
ing VEGF role in EHE growth. VEGF inhibitors may have
therapeutic value: a phase II study reported partial
response to bevacizumab in EHE patients [10]. Sangro re-
ported a case of a young male patient with EHE who was
treated with sorafenib for almost 2 years [11].
Pazopanib has recently been approved by the U.S.
Food and Drug Administration (FDA) and by theis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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advanced renal cancer and soft-tissue sarcomas (STS).
We present here first report of clinical activity of pazo-
panib in EHE with a still ongoing very long term pro-
gression free survival.
Case presentation
A 38 years old female patient, with unremarkable med-
ical history, presented an acute abdominal pain suggest-
ing a cholecystis. Patient had a cholecystectomy and per
operatory, a liver nodule was discovered and biopsied.
The results showed a fibrotic tissue containing poligonal
tumor cells with round nuclei and a relatively scarce
cytoplasm containing vacuolae with sinusoidal growth
pattern. Immunohistochemically, tumor cells had a posi-
tive staining by CD-34, (cytoplasmatic diffuse 100%),
CD-31 (cytoplasmatic diffuse 100%) and was negative to
CK7 and CK20. The final pathologic diagnosis was hep-
atic epitheliod hemangioendothelioma. Then, patient
was followed without any treatment. In March 2001,
patient was recovered in our center, referring right
shoulder pain. A chest and abdominal computed tomog-
raphy (CT) scan showed multiple bilateral pulmonary
nodules and multiples hypodense liver lesions suggestive
of metastases. Surgery was not advised, as disease was
extended to lung and hepatic lesions were bilobar.
Patient started systemic treatment with Doxorubicin
75 mg/m2, every 3 weeks. CT scan evaluation after three
months reported stable disease. Treatment was contin-
ued until six cycles of chemotherapy with stability, and
then patient was followed every 3 month. Ten monthsFigure 1 Computing tomography scan showing multifocal abnormalities,
parenchyma underwent relative hypertrophy. No calcification was visible in
the target lesion was chosen in the right liver, initially measuring 138 × 146
administration of IV contrast material, this main nodule displayed marginal
compressed but remained permeable.after, CT scan showed hepatic progression. Multidiscip-
linary sarcoma committee suggested including patient in
the 62011 study. Patients received Brostacilline for eight
cycles with stability of hepatic lesions for duration of
21 months [12]. Shortly after, the symptoms dramatically
worsened with abdominal pain and digestive haemor-
rhage episode related to a portal hypertension due to the
hepatic invasion. The patient was then proposed to par-
ticipate to a clinical trial testing the GW786034 antian-
giogenic agent within the study 62043 of EORTC [13].
Treatment was started, in December 2005 at 800 mg
daily. Shortly afterwards, patient developed grade 3 hep-
atic toxicity, dose was further reduced to 400 mg allow-
ing transaminase normalisation. After 12 weeks of
treatment, a significant improvement of symptoms was
noticed, analgesic requirement was reduced and hepato-
megaly disappeared. CT scan assessment after 3 months
demonstrated stable hepatic and pulmonary disease
(Figure 1). Side effects reported were grade 2 anaemia
and fatigue. The patient remains on 400 mg of pazopa-
nib without significant toxicities and with ongoing clin-
ical and radiological benefit during than 3 years. Liver
transplantation was discussed but not considered due to
the presence of lung metastasis. Three years after the
beginning of pazopanib, treatment discontinuation was
again required because of grade 2 hepatic toxicity. As
the abdominal pain increased, whereas hepatic biology
improved, patient was rechallenged pazopanib treatment
at 200 mg daily with a progressive increase to 400 mg,
based on a biological monitoring twice a week. Clinical
benefit was rapidly noticed with particularly abdominalinvolving both lobes of the liver. The uninvolved portions of hepatic
itially. In the left liver, lesions coalesce, forming a diffuse pattern. So
mm, extending to the capsular margin with areas of retraction. After
enhancement during the portal phase. Inferior vena cava was
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ity of life.
Patient is still on 400 mg of pazopanib, PS 0, for over
100 months, with stability of the pulmonary nodules, a
minor tumor size reduction observed in the liver and
progressive calcification and tumor shrinkage. Altogether,
using Response Evaluation Criteria In Solid Tumors cri-
teria v. 1.0,10 [14], tumor response consisted in a pro-
longed stabilization (Figures 2, 3 and 4). Importantly an
ectasia of the thoracic was noted on the most recent echo-
cardiography, this anomaly will be carefully monitored.
The role of pazopanib in this phenomenon observed after
8 years of treatment remains unclear but should prompt
further investigations in long term survivors under
VEGFR2 inhibitors including pazopanib.
Discussion
The present case report describes a typical case of
HEHE. The symptoms (abdominal pain, hepatomegaly),
the site of metastases (lung) and the bilobar liver in-
volvement are all characteristic of the initial presentation
of this tumor. This report demonstrates for the first time
that pazopanib is an active treatment, providing a very
long disease control in a patient in third line treatment
of a progressive multimetastatic epithelioid hemangioen-
dothelioma (HEHE). HEHE was first described by Ishak
et al. [15] as a group of rare borderline vascular tumors
with primary liver involvement characterized by the
presence of epithelioid endothelial cells. Although many
patients (25–42%) are asymptomatic at the time of diag-
nosis [7], the most frequent symptoms include pain,
weight loss, fatigue, and jaundice [3,7]. Imaging studiesFigure 2 Chest scanner of November 2007 showing micronodular pulmonhave an important role in the diagnosis of HEHE.
Tumor lesions appear as solid, non- homogenously
hypodense nodules with a ring-like, low-density border,
and a lower-density centre in contrast-enhanced CT im-
aging. Also, magnetic resonance imaging (MRI) shows
non-homogenously hypointense lesions on T1-weighted
images and hypertense lesions on T2-weighted images
(Lin). In this case, the tumoral lesions were observed as
hypodense. The diagnosis of HEHE must be confirmed by
an expert pathologist examination of the tissue. Histo-
pathological characteristics include an invasive growth pat-
tern with preservation of the liver acinar composition and
portal tracts. The tumour consists of epithelioid or den-
dritic cells, which are characterized by large eosinophilic
cytoplasm in a fibromyxoid stroma [16]. In the current
case, both typical tumour architecture and immunohisto-
chemical positivity of endothelial cell markers (such as
CD-31 and CD-34) supported the diagnosis of HEHE.
A small number of single case reports of HEH patients
treated with cytotoxic chemotherapy have been pub-
lished. Patients with EHE still alive 5 years after initial
treatment with a doxorubicin-containing regimen, i.e.
long-term survivors do not exceed 8% [17]. The most
frequently used agent is doxorubicin [18], or its liposo-
mal form [19]. However, the results have been disap-
pointing and HEH is considered a poorly chemosensitive
tumor. VEGF expression’s observed in hepatic EHE
specimens increases interest in employing anti- angio-
genic therapy for this disease. Lenalidomide, sorafenib
and sunitinib were tested in HE treatment and reported
to be efficient in recent cases reports [20-23], and a
phase 2 study [24].ary lesions.
Figure 3 CT scanner of April 2014 showing that the appearance and size of the main lesion remained similar. The target lesion measured
126*137 mm and peripheric calcifications had appeared confirming radiological tumoral control.
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multitargeted TKI interfering with several tumor envir-
onment factors that play a key role in a broad spectrum
of tumor types. Pazopanib is a second-generation small-
molecule TKI with high affinity against VEGFR-1/2/3
and with a lower affinity against PDGFR-α/β, FGFR-1/2
and stem cell factor receptor (c-KitR) [25].
The response achieved in our case was a prolonged
stabilization associated with significant intratumoral
changes. This long progression free survival is interpretedFigure 4 Chest scanner of October 2014 showing stable aspect of lung mto be due to pazopanib effect, because of previous pro-
gression, clinical improvement. In fact, pulmonary nodules
remains stable, whereas minor tumor size reduction was
observed in the liver, with progressive calcification and
tumor shrinkage. Calcification and other changes in tumor
density without clear tumor shrinkage are considered as
highly suggestive of tumor response, especially after the
introduction of the newest antineoplastic molecular-
targeted therapies [26]. Overall, pazopanib was well toler-
ated and the relative lack of side effects compared toicronuodules.
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treatment, reported for the first time. The observation of
aortic ectasia requires further investigation.
In conclusion, pazopanib demonstrated a long
stabilization of HEHE, with dramatic improvement in
clinical status. We think that this treatment is a promising
therapeutic option in patients with HEH. Further research
and prospective studies are required to contribute to the
data regarding the natural history and pazopanib effective-
ness in this rare tumor.
Pazopanib is the first antiangiogenic drug that has
shown successful results in a phase III trial in STS [20].
It was well tolerated in advanced STS and demonstrated
interesting antitumor activity in pretreated patients with
leiomyosarcomas, synovial sarcomas, and other eligible
STS entities.
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